We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Microvascular Complications in Type 1 Diabetes: A Comparative Analysis of Patients Treated with Autologous Nonmyeloablative Hematopoietic Stem-Cell Transplantation and Conventional Medical Therapy.
- Authors
Penaforte-Saboia, Jaquellyne G.; Montenegro, Jr., Renan M.; Couri, Carlos E.; Batista, Livia A.; Montenegro, Ana Paula D. R.; Fernandes, Virginia O.; Akhtar, Hussain; Negrato, Carlos A.; Ribeiro Malmegrim, Kelen Cristina; Moraes, Daniela Aparecida; Dias, Juliana B. E.; Simões, Belinda P.; Gomes, Marilia Brito; Oliveira, Maria Carolina
- Abstract
Objective: To explore the impact on microvascular complications, long-term preservation of residual B-cell function and glycemic control of patients with type 1 diabetes treated with autologous nonmyeloablative hematopoietic stem-cell transplantation (AHST) compared with conventional medical therapy (CT). Research design and methods: Cross-sectional data of patients treated with AHST were compared with patients who received conventional therapy from the Brazilian Type 1 Diabetes Study Group, the largest multicenter observational study in type 1 diabetes mellitus in Brazil. Both groups of patients had diabetes for 8 years on average. An assessment comparison was made on the presence of microvascular complications, residual function of B cell, A1c, and insulin dose of the patients. Results: After a median of 8 years of diagnosis, none of the AHST-treated patients (n = 24) developed microvascular complications, while 21.5% (31/144) had at least one (p < 0.005) complication in the CT group (n = 144). Furthermore, no case of nephropathy was reported in the AHST group, while 13.8% of CT group (p < 0.005) developed nephropathy during the same period. With regard of residual B-cell function, the percentage of individuals with predicted higher C-peptide levels (IDAA1C ≤ 9) was about 10-fold higher in the AHST group compared with CT (75 vs. 8.3%) (p < 0.001) group. Among AHST patients, 54.1% (13/24) had the HbA1c < 7.0 compared with 13.1% in the CT (p < 0.001) group. Conclusion: Patients with newly diagnosed type 1 diabetes treated with AHST presented lower prevalence of microvascular complications, higher residual B-cell function, and better glycemic control compared with the CT group.
- Subjects
DIABETES complications; TYPE 1 diabetes; TREATMENT of diabetes; HEMATOPOIETIC stem cell transplantation
- Publication
Frontiers in Endocrinology, 2017, p1
- ISSN
1664-2392
- Publication type
Article
- DOI
10.3389/fendo.2017.00331